CELYAD ONCOLOGY SA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.308 EUR | -0.32% |
|
+0.16% | -21.03% |
| Apr. 04 | Celyad Oncology SA Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Feb. 09 | Celyad Oncology Seeks Termination of Reporting Obligations to US SEC | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2022 | - | Sales 2023 | 102K 110K | Capitalization | 16.16M 17.42M |
|---|---|---|---|---|---|
| Net income 2022 | -40M -43.14M | Net income 2023 | -8M -8.63M | EV / Sales 2022 | - |
| Net cash position 2022 | 12.19M 13.15M | Net cash position 2023 | 5.95M 6.41M | EV / Sales 2023 | 100 x |
| P/E ratio 2022 |
-0.28
x | P/E ratio 2023 |
-1.19
x | Employees | 18 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 92.37% |
More Fundamentals
* Assessed data
More news
Latest transcript on Celyad Oncology SA
More recommendations
More press releases
More news
| 1 day | +3.56% | ||
| 1 week | +3.90% | ||
| Current month | -1.54% | ||
| 1 month | -3.90% | ||
| 3 months | -11.11% | ||
| 6 months | -42.86% | ||
| Current year | -17.95% |
1 week
0.30
0.33
1 month
0.300.36
Current year
0.300.47
1 year
0.301.28
3 years
0.305.65
5 years
0.3018.50
10 years
0.3070.95
| Managers | Title | Age | Since |
|---|---|---|---|
Michel Lussier
FOU | Founder | 67 | 07-07-23 |
David Georges
DFI | Director of Finance/CFO | - | 18-12-31 |
Eytan Breman
CTO | Chief Tech/Sci/R&D Officer | - | 14-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Michel Lussier
FOU | Founder | 67 | 07-07-23 |
Hilde Windels
CHM | Chairman | 59 | 18-05-06 |
Serge Goblet
BRD | Director/Board Member | - | 07-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-13 | 0.308 | -0.32% | 12 695 |
| 24-05-10 | 0.309 | -3.13% | 5,084 |
| 24-05-09 | 0.319 | +5.11% | 10,014 |
| 24-05-08 | 0.3035 | 0.00% | 7,370 |
| 24-05-07 | 0.3035 | -1.30% | 9,310 |
Real-time Euronext Bruxelles, May 13, 2024 at 05:25 am EDT
More quotes
Celyad Oncology SA is a biotechnology company focused on the discovery and development of innovative technologies chimeric antigen receptor (CAR) T-cell therapies. The company is focusing on opportunities to fully harness the true potential of its proprietary technology platforms and intellectual property and support the development of next-generation CAR T candidates in solid tumors and hematological malignancies.
Calendar
2024-09-20
- Q2 2024 Earnings Release
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -17.95% | 13.79M | |
| +17.96% | 44.96B | |
| +1.17% | 42.65B | |
| +46.62% | 41.85B | |
| -4.27% | 29.04B | |
| +11.42% | 26.08B | |
| -21.39% | 19.03B | |
| +4.86% | 12.75B | |
| +27.29% | 12.06B | |
| -3.50% | 11.75B |
- Stock Market
- Equities
- CYAD Stock
